1. Home
  2. LQDA vs BMA Comparison

LQDA vs BMA Comparison

Compare LQDA & BMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

LQDA

Liquidia Corporation

HOLD

Current Price

$78.03

Market Cap

5.5B

Sector

Health Care

ML Signal

HOLD

Logo Banco Macro S.A.  ADR (representing Ten Class B)

BMA

Banco Macro S.A. ADR (representing Ten Class B)

HOLD

Current Price

$91.29

Market Cap

4.4B

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
LQDA
BMA
Founded
2004
1966
Country
United States
Argentina
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Commercial Banks
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
5.5B
4.4B
IPO Year
2020
2006

Fundamental Metrics

Financial Performance
Metric
LQDA
BMA
Price
$78.03
$91.29
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
11
4
Target Price
$41.00
$99.33
AVG Volume (30 Days)
2.4M
307.5K
Earning Date
05-08-2026
05-27-2026
Dividend Yield
N/A
4.99%
EPS Growth
51.81
N/A
EPS
0.52
N/A
Revenue
$158,320,000.00
N/A
Revenue This Year
$278.87
$16.25
Revenue Next Year
$57.13
N/A
P/E Ratio
$147.92
$33.22
Revenue Growth
1031.18
N/A
52 Week Low
$11.85
$38.30
52 Week High
$78.25
$106.15

Technical Indicators

Market Signals
Indicator
LQDA
BMA
Relative Strength Index (RSI) 75.44 53.35
Support Level $31.23 $84.83
Resistance Level N/A $94.19
Average True Range (ATR) 4.14 4.56
MACD 0.40 -0.97
Stochastic Oscillator 91.55 40.23

Price Performance

Historical Comparison
LQDA
BMA

About LQDA Liquidia Corporation

Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also conducting studies on L606, an investigational, liposomal formulation of treprostinil.

About BMA Banco Macro S.A. ADR (representing Ten Class B)

Banco Macro SA is a financial institution and it provides standard banking products and services designed to suit individual needs. It has two categories of customers, retail customers, which include individuals and entrepreneurs, and corporate customers, which include small, medium, and large companies and corporations. In addition, it provides services to four provincial governments. It generates the majority of its revenue from Argentina.

Share on Social Networks: